Association of KMT2C/D loss‐of‐function variants with response to immune checkpoint blockades in colorectal cancer

Genomic alterations in KMT2 family predict outcome of immune checkpoint therapy in multiple cancers

(2021) Peng Zhang et al.   Journal of Hematology & Oncology

ARID1A deficiency and immune checkpoint blockade therapy: From mechanisms to clinical application

(2020) Guangyuan Hu et al.   CANCER LETTERS

ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy

(2020) Ryosuke Okamura et al.   Journal for ImmunoTherapy of Cancer

Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy

(2020) Jing Li et al.   JOURNAL OF CLINICAL INVESTIGATION

Role of DNA repair defects in predicting immunotherapy response

(2020) Jing Zhang et al.   Biomarker Research

CRISPR-GEMM pooled mutagenic screening identifies KMT2D as a major modulator of immune checkpoint blockade

(2020) Guangchuan Wang et al.   Cancer Discovery

Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors

(2020) Lei Zhang et al.   JAMA Network Open

KMT2A/C mutations function as a potential predictive biomarker for immunotherapy in solid tumors

(2020) Rui Zhang et al.   Biomarker Research

The lysine‐specific methyltransferase KMT2C/MLL3 regulates DNA repair components in cancer

(2019) Theodoros Rampias et al.   EMBO REPORTS

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

(2019) Robert M. Samstein et al.   NATURE GENETICS

Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types

(2019) Feng Wang et al.   JAMA Oncology

Multiomics Prediction of Response Rates to Therapies to Inhibit Programmed Cell Death 1 and Programmed Cell Death 1 Ligand 1

(2019) Joo Sang Lee et al.   JAMA Oncology

Comprehensive analysis of POLE and POLD1 Gene Variations identifies cancer patients potentially benefit from immunotherapy in Chinese population

(2019) Jianfei Yao et al.   Scientific Reports

Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers

(2019) Hao-Xiang Wu et al.   Journal for ImmunoTherapy of Cancer

The Immune Landscape of Cancer

(2018) Vésteinn Thorsson et al.   IMMUNITY

DNA Repair Deficiency and Immunotherapy Response

(2018) Kent W. Mouw et al.   JOURNAL OF CLINICAL ONCOLOGY

ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade

(2018) Jianfeng Shen et al.   NATURE MEDICINE

Cancer immunotherapy using checkpoint blockade

(2018) Antoni Ribas et al.   SCIENCE

Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations

(2018) Judith A. Seidel et al.   Frontiers in Oncology

Co-mutations in DNA damage response pathways serve as potential biomarkers for immune checkpoint blockade

(2018) Jie Wang et al.   CANCER RESEARCH

DNA Damage and Repair Biomarkers of Immunotherapy Response

(2017) Kent W. Mouw et al.   Cancer Discovery

Mutation of cancer driverMLL2results in transcription stress and genome instability

(2016) Theodoros Kantidakis et al.   GENES & DEVELOPMENT

Predictive biomarkers for checkpoint inhibitor-based immunotherapy

(2016) Geoffrey T Gibney et al.   LANCET ONCOLOGY

MLL3/MLL4/COMPASS Family on Epigenetic Regulation of Enhancer Function and Cancer

(2016) Christie C. Sze et al.   Cold Spring Harbor Perspectives in Medicine

Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity

(2015) Michael S. Rooney et al.   CELL

Robust enumeration of cell subsets from tissue expression profiles

(2015) Aaron M Newman et al.   NATURE METHODS

Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer

(2013) Tjalling Bosse et al.   MODERN PATHOLOGY

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE